^
    Back
    Association details:
    Biomarker:EGFR exon 19 deletion
    Cancer:Non Small Cell Lung Cancer
    Drug:Focus V (anlotinib) (Multi-tyrosine kinase inhibitor) +
    Ameile (aumolertinib) (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation

    Excerpt:
    ...Locally advanced or metastatic NSCLC EGFR sensitive mutations (19del and L858R) and TP53 co-mutation; 2....
    Trial ID:
    NCT05778149
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    IASLC-WCLC 2023
    Title:

    Aumolertinib Plus Anlotinib in Advanced NSCLC with Brain Metastasis: A Single-arm, Phase II Study

    Published date:
    08/08/2023
    Excerpt:
    Aumolertinib plus anlotinib showed preliminary efficacy as first-line therapy in EGFR-mutant NSCLC patients with brain metastases. The initial subgroup results demonstrated superior activity of aumolertinib plus anlotinib in patients with multiple intracranial metastases for EGFR 19Del positive.